Boule Diagnostics AB

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0011231158
SEK
5.00
-2.84 (-36.22%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard

1

Poor long term growth as Operating profit has grown by an annual rate -208.64% of over the last 5 years

 
2

The company has declared Negative results for the last 3 consecutive quarters

3

Risky -

4

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

SEK 205 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

1.10

stock-summary
Return on Equity

-40.18%

stock-summary
Price to Book

1.22

Revenue and Profits:
Net Sales:
129 Million
(Quarterly Results - Jun 2025)
Net Profit:
-6 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-36.22%
0%
-36.22%
6 Months
-36.22%
0%
-36.22%
1 Year
-36.22%
0%
-36.22%
2 Years
-36.22%
0%
-36.22%
3 Years
-85.35%
0%
-85.35%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Boule Diagnostics AB for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
3.24%
EBIT Growth (5y)
-208.64%
EBIT to Interest (avg)
-2.33
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
1.04
Sales to Capital Employed (avg)
1.13
Tax Ratio
17.46%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.64%
ROE (avg)
5.22%

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.20
EV to EBIT
-1.16
EV to EBITDA
-1.24
EV to Capital Employed
1.09
EV to Sales
0.73
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-94.25%
ROE (Latest)
-172.02%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -5.62% vs -2.49% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -256.25% vs -139.02% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "129.30",
          "val2": "137.00",
          "chgp": "-5.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "12.80",
          "val2": "7.70",
          "chgp": "66.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "6.50",
          "val2": "3.30",
          "chgp": "96.97%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-4.50",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.70",
          "val2": "-1.60",
          "chgp": "-256.25%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "52.60%",
          "val2": "23.40%",
          "chgp": "2.92%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -2.24% vs 4.23% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -1,286.40% vs 96.85% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "558.50",
          "val2": "571.30",
          "chgp": "-2.24%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-263.90",
          "val2": "67.90",
          "chgp": "-488.66%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "12.50",
          "val2": "11.30",
          "chgp": "10.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-56.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-296.60",
          "val2": "25.00",
          "chgp": "-1,286.40%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-513.60%",
          "val2": "75.70%",
          "chgp": "-58.93%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary

Jun'25
Jun'24
Change(%)
Net Sales
129.30
137.00
-5.62%
Operating Profit (PBDIT) excl Other Income
12.80
7.70
66.23%
Interest
6.50
3.30
96.97%
Exceptional Items
-4.50
0.00
Consolidate Net Profit
-5.70
-1.60
-256.25%
Operating Profit Margin (Excl OI)
52.60%
23.40%
2.92%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is -5.62% vs -2.49% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -256.25% vs -139.02% in Jun 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
558.50
571.30
-2.24%
Operating Profit (PBDIT) excl Other Income
-263.90
67.90
-488.66%
Interest
12.50
11.30
10.62%
Exceptional Items
-56.30
0.00
Consolidate Net Profit
-296.60
25.00
-1,286.40%
Operating Profit Margin (Excl OI)
-513.60%
75.70%
-58.93%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -2.24% vs 4.23% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -1,286.40% vs 96.85% in Dec 2023

stock-summaryCompany CV
About Boule Diagnostics AB stock-summary
stock-summary
Boule Diagnostics AB
Pharmaceuticals & Biotechnology
Boule Diagnostics AB is a Sweden-based company engaged in the provision of medical diagnostic and testing equipment. The Company specializes in the development, manufacture and sale of complete blood count (CBC) systems in the field of hematology. It provides reagents, cleaning products and blood calibrators and controls that are used in human and veterinarian laboratories, as well as analyzers and complementing accessories for hematology systems. The Company’s product portfolio comprises five brands: Clinical Diagnostic Solutions, Exigo, Medonic, Swelab and Quintus. The Company’s primary customer base comprises small and medium-sized hospitals, clinics, diagnostics firms and laboratories. Furthermore, It operates worldwide through a number of subsidiaries, such as Boule Medical AB, Boule Nordic AB, Clinical Diagnostic Solutions Inc and Boule Medical (Beijing) Co Ltd.
Company Coordinates stock-summary
Company Details
Domnarsvgatan 4 , SPANGA None : 163 53
stock-summary
Tel: 46 8 7447700
stock-summary
Registrar Details